Replace exactly what's missing
COAGADEX is the first and only treatment specifically for hereditary factor X deficiency
Problems with bleeding, easy bruising, or swollen joints?
You may have a bleeding disorder.
People with bleeding disorders often have one or more symptoms, which can be mild to severe.
- In women, these symptoms can include heavier or longer bleeding during periods than most other women, or bleeding complications during pregnancy or childbirth.
- Some symptoms can result in pain, like when a joint swells due to bleeding inside the joint.
Wondering if your symptoms are caused by factor X deficiency?
About 1 in 1 million people has factor X deficiency. Are you one of them?
- Factor X deficiency causes problems with blood clotting due to not having enough factor X in the blood. Or sometimes, people have enough factor X but it does not work the way it should.
- People with factor X deficiency may bleed more than most other people and have a hard time getting bleeding to stop.
Are you thinking about trying COAGADEX?
If so, ask your doctor.
COAGADEX replaces exactly what’s missing—factor X
- COAGADEX is the first and only treatment specifically for hereditary factor X deficiency.
- COAGADEX can be taken in different ways—routinely to help prevent bleeding, with surgery to help prevent bleeding, or as needed (on-demand) if bleeding starts.
Indications and Usage for COAGADEX
COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children with hereditary factor X deficiency for:
- Routine prophylaxis to reduce the frequency of bleeding episodes
- On-demand treatment and control of bleeding episodes
- Perioperative management of bleeding in patients with mild, moderate and severe hereditary factor X deficiency
Contraindication for COAGADEX
COAGADEX is contraindicated in patients who have had life-threatening hypersensitivity reactions to COAGADEX.
Important Safety Information for COAGADEX
Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately, contact their physician, and administer appropriate treatment.
The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.
COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.
In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.
